RC2NB

The Research Center for Clinical Neuroimmunology and Neuroscience Basel is an interdisciplinary research institution supported by a non-profit foundation.

[MSJ @MSJ_Research]

Yes👍 from @SofiaSandgren1 @JensKuhle @RC2NB @UniBasel: Blood NfL can provide information on disease activity, prognosis and treatment response, both in drug development trials and in personalised medicine in #MultipleSclerosis.
🔽
https://t.co/NofZKLeiOM

2/🧵

[All Things Multiple Sclerosis @MulSclerosis]

John Dystel Prize for Multiple Sclerosis Research awarded to Dr. Ludwig Kappos for his transformative contributions to MS research
https://t.co/VrLzm7sR1p

[RC2NB @RC2NB]

Our latest Annual Report is out 🚀

Full of insights, milestones, and momentum through research, data innovation, and collaboration.

👉 Get it here: https://t.co/rmLqJ54yPm

[MSJ @MSJ_Research]

In #MultipleSclerosis, treatment effects on blood neurofilament light chain #NfL are moderately associated with therapeutic effects on relapses and MRI lesions.

A meta-regression of randomized controlled trials from @RC2NB @UniBasel_en @unige_en ▶️ https://t.co/rPGvf2rAxN

[MSJ @MSJ_Research]

OCT availability and routine use by neurologists is limited in Switzerland. Awareness, education and guidelines on its clinical use in the care of people with #MultipleSclerosis.

🔓MSJ-ETC study from @Unispital_USZ @RC2NB ▶️ https://t.co/wTOYRZma6I

[MSJ @MSJ_Research]

Deep learning can automate the classification of paramagnetic rim and remyelinated lesions in #MultipleSclerosis, guiding personalized treatment decisions.

Study from @CristinaGranzi2 @RC2NB ▶️ https://t.co/gdZIgsLCiY

[RC2NB @RC2NB]

Check out his profile here:https://t.co/VrrSnV3fWU

[RC2NB @RC2NB]

🎉 Congratulations to Prof. @JensKuhle , Head of the MS Centre @usb_ch and Group Leader @RC2NB, for being named one of Clarivate’s Highly Cited Researchers 2025, ranking among the top 1% most cited scientists worldwide.
#HighlyCited2025 #ResearchExcellence #Neuroscience

[Department of Biomedicine @DepBiomedicine]

New study in Science Translational Medicine (@ScienceMagazine) from @akproebstel and colleagues reveals distinct immune signatures in MOG antibody–associated disease (MOGAD), distinguishing it from MS. Researchers from Zurich, Munich, Toulouse, Lyon, Bonn & Basel (@DepBiomedicine, @DKFBasel, @RC2NB) uncover key immune differences shaping future therapies.

👉🏻 Link: https://t.co/bC64FFcm89

#MOGAD #MSResearch #Neuroinflammation

[RC2NB @RC2NB]

New study led by David Leppert, Roberto Furlan & @JensKuhle shows that specific CSF markers can distinguish MOGAD & NMOSD from MS.
A fast, biology-driven approach for accurate diagnosis in acute demyelination.
https://t.co/aF3xyKm8OF
#MS #MOGAD #NMOSD #Biomarkers

[RC2NB @RC2NB]

🧪 New data from the phase 3 POINT study: combining ponesimod + dimethyl fumarate in relapsing MS did not improve relapse rate, but reduced MRI lesion activity vs DMF alone. Safety was consistent with known profiles.
📄 https://t.co/wyC7VpqUFt

[MS Int'l Federation @MSIntFederation]

MSIF is proud to announce Professor Ludwig Kappos as the 2025 #CharcotAward recipient, honouring a lifetime of impact in #MSResearch. 🏆🔬

From pioneering treatments to mentoring researchers worldwide, his legacy is global. 🌎

Read more: https://t.co/M5phfjV3w9

@RC2NB

[RC2NB @RC2NB]

🚀 Our new website is live!
Explore RC2NB's research, people & purpose — now at https://t.co/WlgLtDBLYT 🧠✨

🎬 Watch the RC2NB Welcome Video for a glimpse into our world.
▶️ https://t.co/UBoG2rnxmc

#RC2NB #Neuroimmunology #MSResearch #WebsiteLaunch

[MSJ @MSJ_Research]

Functional System scores and their corresponding subscores, Ambulation scores and EDSS scores revealed different patterns of disability in #MultipleSclerosis.

Machine learning study using EXPAND trial from @RC2NB @UniBasel_en @UniSpitalBasel ▶️ https://t.co/Z8VCtqARHA

[RC2NB @RC2NB]

🧠 New in Neurol Neuroimmunol Neuroinflamm:
CSF TNF markers + early gray matter damage predict PIRA in early RRMS.
Key predictors: sTNFR1, sTNFR2, LIGHT, cortical lesions, thalamic atrophy.
🔗https://t.co/diBX8menUk
#MS #PIRA #Neuroinflammation #MRI #CSF #MultipleSclerosis

[Lars G. Hemkens @LGHemkens]

Just 24 participants to go:
Our Swisswide pragmatic #MultiSCRIPT trial is close to reaching 915 in about a year.
Only possible through full embedding in routine care and with an outstanding team @RC2NB and #SMC and the wonderful support of our patients.

https://t.co/6karLoUXBe

[RC2NB @RC2NB]

In RC2NB’s Annual Report, real patient stories highlight why personalized treatments & cutting-edge research matter. Together, we’re shaping the future of MS care. #MS #Research #PatientVoices

[RC2NB @RC2NB]

We are pleased to present the @RC2NB Annual Report 2024, highlighting a year of progress, key milestones, and scientific advancements across our four core workstreams. 📖 Read the full report here: https://t.co/Llep5S3uPg

[RC2NB @RC2NB]

Feb 11 – International Day of Women & Girls in Science! 🚀 At #RC2NB & @ThINk_Basel , this day is every day. Leading the way? Prof. Cristina Granziera, championing brilliant women who shape the future of #STEM.🔬💡 #WomenInScience #IDWGS #MSresearch

[RC2NB @RC2NB]

@RC2NB joined the MS State of the Art Symposium 2025 on "Lifestyle in MS: Sports, Nutrition, & Brain Health."
Proud to see @ThINk_Basel & @JensKuhle represent RC2NB, with our team sharing research on:
🔬 MultiSCRIPT
🔬 Complement activation in MS
🔬 B cell therapies